Drug intelligence / Profile preview

rifaximin + omeprazole + polyethylene glycol 3350

Development stage: Unknown
Lead developer: Alfa Wassermann
Modality: Small Molecules
Administration: Oral

Overview

A combination of **rifaximin** (a gastrointestinal-specific antibiotic with low bioabsorption), **omeprazole** (a proton pump inhibitor), and **polyethylene glycol 3350** (an osmotic laxative). Each component has distinct mechanisms and uses. Rifaximin is used for treating hepatic encephalopathy and other gastrointestinal conditions. Omeprazole reduces stomach acid production. Polyethylene glycol 3350 treats constipation by drawing water into the intestines to soften stool.

Targets

Colonic lumen osmotic environmentrpoB (DNA-directed RNA polymerase subunit beta)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on rifaximin + omeprazole + polyethylene glycol 3350.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rifaximin + omeprazole + polyethylene glycol 3350.

Explore the full profile